Closing Bell Overtime: CRISPR Therapeutics CEO On Milestone FDA Approval; Rick Caruso On Potential Macys Sale 12/11/23
b'Major averages notched their third straight positive session. Wells Fargo\\u2019s Scott Wren and CFRA\\u2019s Sam Stovall break down the market action. Jefferies analyst Brent Thill breaks down Oracle\\u2019s revenue miss. Caruso Founder Rick Caruso talks rumors of a Macy\\u2019s sale and the broader state of commercial real estate. CRISPR Therapeutics CEO Sam Kulkarni on his company\\u2019s partnership with Vertex Pharma leading to breakthrough FDA approval for a sickle cell treatment, the first in US to be approved that uses CRISPR gene-editing technology.'